PHARMACEUTICAL FORMULATION 514
    1.
    发明授权
    PHARMACEUTICAL FORMULATION 514 有权
    药剂师514

    公开(公告)号:EP2346495B1

    公开(公告)日:2016-07-20

    申请号:EP09740728.2

    申请日:2009-10-05

    IPC分类号: A61K31/502 A61K47/32

    摘要: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

    摘要翻译: 本发明涉及药物制剂,其包含药物4-固体分散体中的4- [3-(4-环丙烷羰基 - 哌嗪-1-羰基)-4-氟 - 苄基] -2H-酞嗪-1-酮与基质聚合物 其具有低吸湿性和高软化温度,例如共聚维酮。 本发明还涉及由这种制剂提供的药物的每日药物剂量。 此外,本发明涉及使用4- [3-(4-环丙烷羰基 - 哌嗪-1-羰基)-4-氟 - 苄基] -2H的固体分散体中具有低吸湿性和高软化温度的基质聚合物 β-萘啶-1-酮,用于提高药物的生物利用度。